MALVERN, PA, December 8, 2017
Ocugen, Inc., a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies and novel biologics that address rare and underserved ocular diseases, today announced its Co-Founder, Chairman and Chief Executive Officer Shankar Musunuri, Ph.D., MBA, was named one of the “Most Admired CEO’s in 2017” by the Philadelphia Business Journal.
The Editorial Board of the Philadelphia Business Journal sought candidates with a strong record and vision on innovation in their field, outstanding financial performance, a commitment to diversity in the workplace, and for those who have made contributions to the Greater Philadelphia region.
“Having worked closely with Dr. Musunuri for several years prior to his founding of Ocugen, I know firsthand the skillset and enthusiasm he brings to motivate his team as it advances novel ocular biologics through the clinic,” said Frank N. Leo, an Ocugen Board Director. “The other board members and I continue to be impressed by his commitment to excellence and compassion for those around him, which is the driving force behind the company and it impacts everyone at Ocugen.”
Dr. Musunuri is a seasoned biotech veteran with more than 24 years of results-driven experience that includes advancing and commercializing a diverse portfolio of products for numerous companies ranging from “Big Pharma” to novel start-up biotechs.
“It was William Shakespeare who once said, ‘the eyes are the window to your soul,’ and to be able to work in a space that touches people so deeply is something I take very personally,” said Dr. Musunuri. “Our mission is to provide treatment options to millions of patients who are not being served by the current standard of care or for whom no effective treatments currently exist. I am humbled by the Editorial Board’s decision to include me on this year’s prestigious list.”
Dr. Musunuri takes a personal interest in those who work at Ocugen and focuses on providing every employee the opportunity to grow and develop through stretch goals and assignments. Building a high performing team is his focus, ensuring every employee has the tools and resources to work at their top potential.
About Ocugen, Inc.
Ocugen, Inc. is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies and novel biologics that address rare and underserved ocular disorders. Ocugen is aggressively pursuing new treatments for ocular graft versus host disease (OCU300), dry eye disease (OCU310), retinitis pigmentosa (OCU100) and wet AMD (OCU200). Our lead programs OCU300 and OCU310 are expected to enter pivotal clinical trials in 2018. In addition, OCU300 received the first and only orphan drug designation for ocular graft versus host disease from the Food and Drug Administration (FDA) providing certain regulatory and economic benefits. For more information, please visit www.ocugen.com.
Investor Relations Contact: